Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Lebrikizumab Formulations in Healthy Subjects
NCT02486809Phase 1Completed
- Sponsor
- Genentech
- Start
- Jul 2015
- Primary completion
- Oct 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lebrikizumab in asthma and atopic dermatitis (AD) (2 arms), sponsored by Genentech. Primary endpoints: Maximum observed concentration, Time to maximum concentration and 5 more. Started Jul 2015; status: completed.
02
Drugs
lebrikizumab
03
Conditions
asthmaatopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02486809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02486809.